Author Archives: Scalper1

Arbitrage Alert! Closed-End Funds At Divergent Valuations

Summary BME and THQ are closed-end funds with similar investment objectives and portfolios which have been well correlated historically. The funds are currently trading at wildly divergent premium/discount valuations. Long/short traders should consider a pair trade of long THQ, short BME. BME has filed for a secondary offering of shares that represents more than 20 days’ volume, adding further downward pressure to that fund. As any investor even moderately familiar with the world of closed-end fund (CEF) investing knows, funds rarely trade at net asset value. Funds’ market-determined prices can be at a premium to – or more frequently, a discount to – net asset value (NAV). Theories abound about why the market tends to “love” or “hate” funds at a given time. However, to state the obvious, the market tends to feel similarly about similar funds. For instance, currently, the market hates funds that focus on high yield bonds, while favoring funds that focus on lower yielding, higher quality bonds. As a result, premium/discount arbitrage can be tricky since it creates risk that the market proves correct in its love and hatred of different categories of funds (hint: the market is often quite wrong). Currently, however, there exists an interesting arbitrage pair trade between two similar biotech funds, BME and THQ, which exist on opposite ends of the market’s love/hate continuum. Similar Funds BlackRock Health Sciences Trust (NYSE: BME ) is a well established, non-diversified fund which focuses on healthcare equity investments, with an option writing overlay for added income. From the sponsor website: BlackRock Health Sciences Trust’s (the ‘Trust’) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust utilizes an option writing (selling) strategy to enhance dividend yield. Tekla Healthcare Opportunities Fund (NYSE: THQ ) is a younger fund that was launched by Tekla just over a year ago to focus on a similar segment of healthcare-related equity investments. From Tekla’s website: Tekla Healthcare Opportunities Fund (“THQ”) is a non-diversified closed-end fund traded on the New York Stock Exchange under the ticker THQ. THQ employs a versatile investment strategy with broad access to opportunities within 11 sub-sectors of healthcare and has the ability to invest across a company’s full capital structure. While there are some differences in scope, (BME uses option writing while THQ has been active in convertible debt), the two funds are remarkably similar in their asset allocations, in some cases making major investments in identical equities [Biogen Inc. (NASDAQ: BIIB ), Celgene Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Company (NYSE: BMY )] and in others choosing close competitors. Source: cefconnect.com, Fund SEC filings Unsurprisingly, given the similarity in holdings, the funds’ net asset values have generally moved in lock-step, with a correlation of daily NAV changes of 0.94 ( source: Convergence Investments analysis) during the past 12 months. (click to enlarge) Source: Yahoo! finance Divergent Valuations Despite the funds’ quite similar portfolios and NAV performance, the market is (currently) valuing the funds quite differently. As of closing on 8/18, THQ traded at -10.5% discount to NAV while BME traded at a 8.1% premium , implying that BME investors are willing to spend 21% more for a similar basket of investments. BME Premium/Discount YTD (click to enlarge) THQ Premium/Discount YTD (click to enlarge) Source: cefconnect.com The Trade While 10% discounts or 8% premiums are both within the range of normal for closed-end funds, the simultaneous existence of both in similar funds is quite rare. The trade implied by this temporary market mispricing is fairly straightforward. Long/short investors should consider long THQ, short BME. Given the funds’ high cross correlation and relatively similar beta risk (BME: 0.63, THQ: 0.69, source: Convergence Investments analysis ), it would not be unreasonable to use 1:1 ratio for a market neutral position. Long-only investors considering investment in BME should strongly consider the alternative of THQ and those with current positions in BME may consider rotating into THQ. I should note, however, that my firm takes no view for or against the healthcare sector so long-only investors should consider their attraction to sector exposure in addition to the many other factors to consider regarding suitability for any investor’s unique circumstances. A Potential Catalyst Finally, Blackrock’s BME fund recently filed definitive materials with the SEC on 8/12/15 for a 453,000 share secondary offering. While the share distributors will undoubtedly seek to sell into the market gradually, this share count is more than 20x average daily volumes so is likely to introduce some downward pressure, especially if share distributors see narrowing premiums. Disclosure: I am/we are long THQ. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Additional disclosure: Also, currently short BME. Convergence Investment Management may recommend various securities included within this article for inclusion for individual client portfolios. These recommendations may change at any time and are specific to the individual client’s objectives and risk tolerance.

Quarterly Financial Reporting Is Needed, Productive, And Good

The following may be controversial. It also may be dull to the point that you might not care. Here’s why you should care: quarterly reporting is a useful and productive use of corporate resources, and it would be a shame to lose it because some people with a patina of intelligence think it is harmful. Who knows? Losing it might even make you poorer. The cause for this article is a piece from the Wall Street Journal, Time to End Quarterly Reports, Law Firm Says . Here’s the first two sentences: Influential law firm Wachtell, Lipton, Rosen & Katz has an idea that may be music to the ears of its big corporate clients and a nightmare for some investors and analysts: end quarterly earnings reports. Wachtell on Tuesday called on the Securities and Exchange Commission to consider allowing U.S. companies to do away with the obligatory updates, one of the most important rituals on Wall Street and in corporate America, suggesting that they distract executives from long-term goals. The basic case is that quarterly earnings lead companies to behave in a short-term manner, and underinvest for longer-term growth, thus hurting the US economy. I disagree. There are at least four things that are false in the arguments made in the article, and in books like Saving Capitalism from Short-Termism : Quarterly earnings don’t produce value in and of themselves Quarterly earnings cause most corporations to ignore the long-term. Ending quarterly earnings will end activism, buybacks, and dividends. Buybacks and dividends are bad uses of capital, and more capital investment, especially for long-dated projects, is necessarily a good thing. Why Quarterly Earnings are Valuable I’ve written a number of articles about quarterly earnings and estimates of those earnings: Earnings Estimates as a Control Mechanism, Flawed as they are , and Earnings Estimates as a Control Mechanism, Flawed as they are, Redux . The basic idea is this: quarterly earnings results give investors an idea as to whether the companies remain on their long-term growth path or not. As I wrote: Most of the value of a Corporation on a going concern basis stems from the future earnings of the company. Investors want to have an estimate of forward earnings so that they can gauge whether the company is growing at an appropriate rate. Now, it wouldn’t matter if the system were set up by third-party sell side analysts, by buyside analysts, by companies themselves, or by a combination thereof. The thing is investors are forward-looking, and they want a forward-looking estimate to allow them to estimate whether the companies are doing well with their current earnings or not. Don’t think of the quarterly earnings in isolation. A good or bad quarterly earnings number conveys information not about the current period only, but about all future periods. A bad earnings number lowers the estimates of all future earnings, telling market players that the long-term efforts of the company are not going to be so great. Vice-versa for a good number. Now, in some cases, that might not be true, and the management team will say, “But we still expect our future earnings to reach the levels that we expected before this quarter.” That still leaves the problem of getting to the high future earnings, which if missed will lead the market to reprice the stock down. They might also use a non-GAAP measure of earnings to explain that earnings are not as bad as they might seem. In the short-run the market may accept that, but if you do that often enough, eventually the markets factor in the many “one-time” adjustments, and lower the earnings multiple on the stock to reflect the reduced quality of earnings. In addition, having shorter-term targets causes corporations to not get lazy in managing expenses and capital. When the measurement periods get too long, discipline can be lost. Quarterly Earnings Don’t Cause Most Firms to Neglect the Long-Term Firms aren’t interested in only the current period’s earnings, but about the entire future path of earnings. Even if the current period’s earnings meet the estimates, the job is not done. If there aren’t plans to grow earnings for the next 3-5 years, eventually earnings won’t meet the expectations of investors, and the price of the stock will fall. The short-term is just the beginning of the long-term. It is not either/or but both/and. A company has to try to explain to investors how it is growing the value of the firm – if present targets aren’t being met, why should there be any confidence that the future will be good? Think of corporate earnings like a long-term project which has a variety of things that have to be done en route to a significant goal. The quarterly earnings measure whether the progress toward completing the goal is adequate or not. Now, the measure is not perfect, but who can think of a better one? Ending Quarterly Earnings Would Not End Activism, Buybacks, and Dividends I can think of an area in business where earnings estimates don’t play a role – private equity. Are the owners long-term oriented? Yes. Are they short-term oriented? Yes. Is capital managed tightly? Very tightly. All excess capital is dividended back – it as if activists run the firms permanently. If there were no quarterly earnings in the public equity markets, firms would still be under pressure to return excess capital to shareholders. Activists would still analyze companies to see if they are badly managed, and in need of change. If anything, when companies would release their earnings less frequently, the adjustments to the market price of the stock would be more severe. Companies that disappoint would find the activists arriving regardless of the periodicity of the release of earnings. On the Use of Excess Capital Investing, particularly for the long-term, is not risk-free. In an environment where there is rapid technological change, like there is today, it is difficult to tell what investments will not be made obsolete. In such an environment, it can make a lot of sense to focus on shorter-term investments that are more certain as to the success of the project. It is also a reason why dividends and buybacks are done, as capital returned to shareholders is associated with higher stock prices, because the capital is used more efficiently. Companies that shrink their balance sheets tend to outperform those that grow them. As an example, large acquisitions tend not to benefit shareholders, while small acquisitions that lead to greater organic growth do tend to benefit investors. The same is true of large versus small investments for organic growth away from M&A. Most management teams can adequately estimate and plan for the growth that stems from incremental action. Large revolutionary investments are another thing. There is usually no way to estimate how those will work out, and whether the prospects are reasonable or not. In one sense, it’s best to leave those kinds of investment projects to highly focused firms that do only that. That’s how biotech firms work, and it is why so many of them fail. The few winners are astounding. Or, think about how progressive Japanese firms were viewed to be in the 1980s, as they pursued long-term projects that had very low returns on equity. All of that failed, to a first approximation, while the derided American model of shareholder capitalism prospered, as capital was used efficiently on projects with high risk-adjusted returns, and not wasted on speculative projects with uncertain returns. The same will prove true of China over the next 20 years as they choke on all of their bad investments that yield low returns, if indeed the returns are positive. Remember, bad investments are just expenses in fancy garb – it just takes the accounting longer to recognize the losses. Think of Enron if you need an example, which brings up one more point: good investing focuses on accounting quality. Accrual items on the asset side of the balance sheets of corporations get higher valuations the shorter the accrual is, and the more likely it is to produce cash. Most long term projects tend to be speculative, and as such, drag down the valuation of the stock, because in most cases, it lowers the long-term earnings of the company. Conclusion If quarterly earnings are abolished, intelligent corporations won’t change much. Investment won’t go up much, and the time horizon of most management teams will not rise much. If you need any proof of that, look at how private equity and large mutual insurers manage their firms – they still analyze quarterly results, and are conservative in how they deploy capital. The only great change of eliminating quarterly earnings will be a loss of quality information for equity investors. Bond investors and banks will still require more frequent financial updates, and equity investors may try to find ways to get that data, perhaps through the rating agencies. Disclosure: None